Lupin Ltd, a leading Indian pharmaceutical company, has launched Liraglutide injection in the United States, marking a significant expansion of its complex injectables portfolio. The injectable is aimed at improving blood sugar control in adults and children aged 10 years and above with Type 2 Diabetes, in combination with diet and exercise.
Product Details
- Dosage Form: 18 mg/3 mL single-patient prefilled pen
- Therapeutic Use: Blood sugar management for Type 2 Diabetes
- Bioequivalence: Comparable to Victoza® by Novo Nordisk, which has annual US sales of USD 350 million
“We are pleased to launch Liraglutide Injection in the US. This highlights our commitment to making essential therapies accessible to patients,” said Spiro Gavaris, President – US Generics, Lupin.
Other USFDA Approvals
Lupin also announced:
- Rivaroxaban Oral Suspension (1 mg/mL): Bioequivalent to Xarelto® oral suspension (Janssen Pharmaceuticals). Indicated for venous thromboembolism (VTE) treatment in pediatric patients and thromboprophylaxis in children post-Fontan procedure. Manufactured at Lupin’s Chhatrapati Sambhajinagar facility.
- Generic Biktarvy® Tablets: Tentatively approved for HIV treatment, containing bictegravir, emtricitabine, and tenofovir alafenamide. Manufactured at Nagpur facility, with Biktarvy® US sales estimated at USD 16.2 billion (IQVIA MAT July 2025).
Strategic Significance
These launches strengthen Lupin’s footprint in the US market, enhance its portfolio of complex injectables and generics, and support its mission of providing affordable, high-quality therapies to patients globally.
Summary
- Liraglutide Injection: Launched in the US for Type 2 Diabetes, bioequivalent to Victoza®.
- Rivaroxaban Oral Suspension: USFDA approved for pediatric VTE and thromboprophylaxis.
- Generic Biktarvy® Tablets: Tentatively approved for HIV treatment.
- Impact: Expands Lupin’s US generics portfolio, reinforcing presence in complex injectables and high-value therapies.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.